- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Northfield Today
By the People, for the People
Medline and BioSig Technologies Compared in New Analysis
Analysts see more upside potential in Medline stock compared to BioSig Technologies
Mar. 20, 2026 at 8:42am
Got story updates? Submit your updates here. ›
A new analysis from Transcript Daily compares medical device manufacturers Medline and BioSig Technologies. The report finds that Medline has higher revenue and earnings than BioSig, and analysts believe Medline has stronger growth prospects and more potential upside. The article examines the financial performance, valuation, and analyst recommendations for both companies.
Why it matters
This analysis provides investors with a side-by-side comparison of two medical device companies, highlighting their relative strengths and weaknesses. It could help investors make more informed decisions about which stock to potentially invest in based on the companies' financial metrics, growth potential, and analyst sentiment.
The details
The report finds that Medline has higher revenue and earnings per share than BioSig Technologies. Medline also has stronger institutional ownership, which is seen as an indicator of the company's long-term potential. Analysts have a more favorable consensus rating and higher price target for Medline compared to BioSig, suggesting they believe Medline is the better investment option of the two.
- The analysis was published on March 20, 2026.
The players
Medline
A leading provider of medical-surgical products and supply chain solutions serving healthcare providers across the full range of care settings.
BioSig Technologies
A medical device company that develops proprietary technology to enhance the cardiac ablation procedures used to treat atrial fibrillation.
The takeaway
This analysis suggests that Medline, with its larger scale, stronger financials, and more favorable analyst sentiment, may be the better investment option compared to the smaller and less profitable BioSig Technologies. Investors looking to gain exposure to the medical device industry could find Medline's diversified product portfolio and integrated supply chain capabilities appealing.
